Prostate Cancer Recurrence Risk Higher With Extensive Positive Margins
In a study, just 12.1% of cases with focal positive surgical margins (PSM) experienced biochemical recurrence compared with 54.1% of those with extensive PSM.
Prostate Cancer News
PROSTATE ADVISOR
Prostate Cancer News
SABR May Up Survival in Oligometastatic Cancers
New data from a phase 2 randomized trial suggest that stereotactic ablative radiotherapy to sites of metastases may prolong overall and progression-free survival.
BPH Meds Found to Delay Prostate Cancer Diagnosis
Men treated with 5-alpha reductase inhibitors were diagnosed with prostate cancer 2 years later than men not using these drugs.
Testosterone Therapy Safe Despite Prostate Cancer
New studies find no increase in biochemical recurrence risk following radical prostatectomy or radiation therapy associated with testosterone replacement therapy.
Darolutamide Gets Priority Review for Non-Metastatic Castration-Resistant Prostate Cancer
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for darolutamide (Bayer and Orion), an investigational treatment for non-metastatic castration-resistant prostate cancer (nmCRPC).
Single-Dose Brachytherapy Effective for Prostate Cancer
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease
Morbidity Low With Focal Laser Ablation of Prostate Cancer
Focal laser ablation (FLA) of low- to intermediate-risk prostate cancer is associated with low morbidity and good oncologic outcomes.
Agent Orange Possibly Protective in Prostate Cancer ADT Recipients
New study finds that Vietnam War exposure to the defoliant Agent Orange is associated with a reduced death risk among men receiving androgen deprivation therapy for advanced prostate cancer.
Biparametric MRI May Suffice for Prostate Cancer Detection
Biparametric MRI detects prostate tumors with an accuracy similar to that of multiparametric MRI without the cost and risks associated with intravenous gadolinium contrast.
Investigating CD133 as a Biomarker of Prostate Cancer Disparity in African American Men
CD133 has often been used as a marker of cancer stem cells.
Investigational Antiandrogen Drug Delays Metastasis in CRPC
Among men with nonmetastatic castration-resistant prostate cancer, those who were treated with darolutamide had a 59% decreased risk of metastasis compared with placebo recipients.
Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
Newer mCRPC Drugs Led to Longer Survival in African American Patients
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
Metastatic Prostate Cancer Responds to Novel Radiation Therapy
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
PCa Genomic Test May Predict Outcomes More Accurately in African-American Men
The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.
Radium-223 Combination Found Not Beneficial For Certain Patients With Castration-Resistant Prostate Cancer
Patients with metastatic CRPC and bone metastases treated with abiraterone plus prednisone/prednisolone had a higher risk of bone fractures when receiving concomitant radium-223.
Prostate Cancer Active Surveillance Increasing in the US
From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.
Current Guidelines for Germline Genetic Testing in Prostate Cancer May Be Insufficient
A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.
MSI-H/dMMR Is Clinically Meaningful, Despite Being Uncommon in Prostate Cancer
Biomarkers of PD-1/PD-L1 checkpoint inhibitor response in prostate cancer could help stratify patients by response.
Overactive Bladder Linked to Prostate Cancer ADT
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
Want to read more?
Please login or register first to view this content.
